A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
A Multicenter, Randomized, Blinded, Placebo-Controlled Confirmatory Clinical Trial of Autologous REGEND001 Cell Therapy for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Chronic obstructive pulmonary disease (COPD) is a common, progressive, and heterogeneous respiratory disorder. It is associated with substantial morbidity and mortality worldwide, leading to progressive decline in lung function, impaired quality of life, and a significant healthcare burden. REGEND001, made from airway basal stem cells with ability to regenerate lung tissue, is promising to COPD treatment. In this study, a multicenter, randomized, blinded, placebo-parallel-controlled trial is performed to verify the efficacy and safety of REGEND001 in treatment of COPD patients with emphysema.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Shiyue Li, Professor and Chief Physician
- Número de teléfono: 86-20-83062114
- Correo electrónico: lishiyue@188.com
Ubicaciones de estudio
-
-
Guangdong
-
Guangzhou, Guangdong, Porcelana
- The First Affiliated Hospital of Guangzhou Medical University
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male or female, aged 40-75 years;
- Diagnosed with COPD;
- Post-bronchodilator FEV1/FVC <0.7
- Emphysematous lesions demonstrated by HRCT;
- Hemoglobin-corrected DLCO%predicted ≥20% and <70%;
- Post-bronchodilator FEV1%predicted ≤80%;
- COPD Assessment Test (CAT) score ≥3;
Exclusion Criteria:
- History of ≥2 COPD exacerbations leading to hospitalization within 1 year prior to screening, or a COPD exacerbation leading to hospitalization within 2 months prior to screening;
- Current or previous history of malignancy;
- An assessed life expectancy of <1 year;
- Respiratory tract infection or systemic infection requiring treatment, or severe localized infection within 4 weeks prior to screening;
- History of invasive or non-invasive mechanical ventilation within 4 weeks prior to screening;
- Diagnosis of pneumonia within 3 months prior to screening;
- Abnormal coagulation function affecting the safety of fiberoptic bronchoscopy procedures at screening;
- Subjects requiring long-term maintenance anticoagulant therapy or antiplatelet therapy, who are unable to discontinue such medications for at least 1 week prior to cell collection and cell infusion;
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador de placebos: Placebo
Participants randomized to the Placebo Comparator arm will receive a single administration of placebo. |
Participants enrolled will have a bronchoscopy with brushing for cell collection, followed by a single adiministratoin of placebo via bronchoscopy and 1 year of follow-up. |
|
Experimental: REGEND001
Participants randomized to the experimental arm will receive a single administration of REGEND001. |
Participants enrolled will have a bronchoscopy with brushing for cell collection, followed by a single adiministratoin of REGEND001 via bronchoscopy and 1 year of follow-up. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline in the measured Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)
Periodo de tiempo: Week 52 after treatment
|
The change from baseline in measured DLCO is defined as the difference between the absolute measured DLCO value at baseline and that measured at the assessment time point after treatment. |
Week 52 after treatment
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change from baseline in COPD Assessment Test (CAT) score
Periodo de tiempo: Week 12, 24 and 52 after treatment
|
The COPD Assessment Test (CAT) is an 8-item questionnaire used to assess the impact of COPD on health status. The total score ranges from 0 to 40, with higher scores indicating a greater impact of COPD and worse health status. Change from baseline is calculated as the post-treatment CAT score minus the baseline CAT score. |
Week 12, 24 and 52 after treatment
|
|
Proportion of subjects with a ≥2-point improvement or worsening from baseline in CAT score
Periodo de tiempo: Week 12, 24 and 52 after treatment
|
Minimal clinically important difference for CAT is recognized as 2 points. |
Week 12, 24 and 52 after treatment
|
|
Change from baseline in DLCO
Periodo de tiempo: Week 12, 24 and 52 after treatment
|
DLCO is assessed by absolute measured value, hemoglobin (Hb)-corrected measured/predicted ratios and corresponding area under curve (AUC). |
Week 12, 24 and 52 after treatment
|
|
Proportion of subjects with a ≥11% relative improvement or worsening from baseline in absolute measured DLCO
Periodo de tiempo: Week 12, 24 and 52 after treatment
|
Minimal clinically important difference (MCID) of DLCO is recognized as 11%. |
Week 12, 24 and 52 after treatment
|
|
Change from baseline in alveolar volume (VA)
Periodo de tiempo: Week 12, 24 and 52 after treatment
|
VA is assessed by measured values, measured/predicted ratio and corresponding area under curve (AUC). |
Week 12, 24 and 52 after treatment
|
|
Change from baseline in forced expiratory volume in the first second (FEV1) post-bronchodilator
Periodo de tiempo: Week 12, 24 and 52 after treatment
|
FEV1 is assessed by measured value, measured/predicted ratio and corresponding area under curve (AUC). |
Week 12, 24 and 52 after treatment
|
|
Change from baseline in 6-minute walk distance (6MWD)
Periodo de tiempo: Week 12, 24 and 52 after treatment
|
6MWD is assessed by the measured value and corresponding area under curve |
Week 12, 24 and 52 after treatment
|
|
Proportion of subjects with a ≥30-meter change from baseline in 6MWD
Periodo de tiempo: Week 12, 24 and 52 after treatment
|
Minimal clinically important difference (MCID) of 6MWD is recognized as 30 meters. |
Week 12, 24 and 52 after treatment
|
|
Change from baseline in St. George's Respiratory Questionnaire for COPD (SGRQ-C) score
Periodo de tiempo: Week 12, 24 and 52 after treatment
|
The St. George's Respiratory Questionnaire for COPD (SGRQ-C) is a validated disease-specific patient-reported outcome measure used to assess the impact of COPD on patients' health status and quality of life. Total score, ranged from 0 to 100, is the sum of points from all items. A higher value represents a worse outcome. |
Week 12, 24 and 52 after treatment
|
|
Proportion of subjects with a ≥4-point improvement or worsening from baseline in SGRQ-C score
Periodo de tiempo: Week 12, 24 and 52 after treatment
|
Minimal clinically important difference for SGRQ is recognized as 4 points. |
Week 12, 24 and 52 after treatment
|
|
Annualized rate of COPD exacerbations (AECOPD), adjusted for prior exacerbation history and baseline characteristics
Periodo de tiempo: Week 52 after treatment
|
The annualized rate of COPD exacerbations (AECOPD), adjusted for prior exacerbation history and baseline characteristics, represents the adjusted frequency of acute exacerbations of COPD over the assessment period. |
Week 52 after treatment
|
|
Change from baseline in arterial blood gas parameters
Periodo de tiempo: Week 52 after treatment
|
The change from baseline in arterial blood gas parameters reflects changes in gas exchange function and respiratory status over the assessment period. |
Week 52 after treatment
|
|
Change from baseline in HRCT images
Periodo de tiempo: Week 52 after treatment
|
HRCT images are quantitatively analyzed using dedicated software to measure emphysema volume (mL) and functional lung volume (mL). |
Week 52 after treatment
|
|
Adverse Event
Periodo de tiempo: Hour 24, Week 12, 24 and 52 after treatment
|
An adverse event (AE) is any untoward medical occurrence in a subject who has received a study intervention, regardless of whether or not it is considered related to the intervention. |
Hour 24, Week 12, 24 and 52 after treatment
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- REGEND001-COPD-251
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .